¼¼°èÀÇ ±Þ¼º ô¼ö ¼Õ»ó ½ÃÀå
Acute Spinal Cord Injury
»óǰÄÚµå : 1744923
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 274 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,106,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,320,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ±Þ¼º ô¼ö ¼Õ»ó ½ÃÀåÀº 2030³â±îÁö 87¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 67¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ±Þ¼º ô¼ö ¼Õ»ó ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 4.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 87¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿ÏÀü ô¼ö ¼Õ»óÀº CAGR 5.2%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 62¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºÒ¿ÏÀü ô¼ö ¼Õ»ó ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 2.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 18¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ±Þ¼º ô¼ö ¼Õ»ó ½ÃÀåÀº 2024³â¿¡ 18¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 18¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 8.3%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.8%¿Í 3.5%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.6%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ±Þ¼º ô¼ö ¼Õ»ó(SCI) Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

±Þ¼º ô¼ö ¼Õ»óÀÌ ÀÀ±Þ, ¿Ü»ó, ½Å°æ ÀçȰ ÀÇ·á¿¡¼­ Áß¿äÇÑ Ä¡·á ¿ì¼±¼øÀ§ÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

±Þ¼º ô¼ö¼Õ»ó(SCI)Àº °©ÀÛ½º·¯¿î ¿Ü»ó¼º »ç°ÇÀ¸·Î ÀÎÇØ ¼Õ»ó ºÎÀ§ ¾Æ·¡ÀÇ °¨°¢, ¿îµ¿ ¹× ÀÚÀ²½Å°æ ±â´ÉÀÌ ºÎºÐÀûÀ¸·Î ¶Ç´Â ¿ÏÀüÈ÷ ¼Õ»óµÇ´Â °ÍÀ¸·Î, SCI´Â °¡Àå º¹ÀâÇϰí Ä¡¸íÀûÀÎ ½Å°æÇÐÀû ÀÀ±Þ»óȲ Áß ÇϳªÀ̸ç, Á¾Á¾ ±³Åë»ç°í, ³«»ó, ½ºÆ÷Ã÷ ¿Ü»ó, Æø·Â µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ÇãÇ÷, ¿°Áõ, ÈïºÐ µ¶¼ºÀ¸·Î ÀÎÇÑ µ¹ÀÌų ¼ö ¾ø´Â ÀÌÂ÷ Àå¾Ö´Â Ãʱ⠿ܻó ÈÄ ºü¸£°Ô ¹ß»ýÇÏ¿© Àå±âÀûÀÎ Àå¾Ö¸¦ ¾ÇÈ­½Ã۱⠶§¹®¿¡ Áï°¢ÀûÀÎ °³ÀÔÀÌ ÇʼöÀûÀÔ´Ï´Ù.

»çȸÀû, °æÁ¦Àû ºÎ´ãÀÌ Å©±â ¶§¹®¿¡ ±Þ¼º±â SCI´Â Àü ¼¼°èÀûÀ¸·Î ¿Ü»ó ¹× ½Å°æ¿Ü°ú ÇÁ·ÎÅäÄÝ¿¡¼­ Á¡Á¡ ´õ ¿ì¼±¼øÀ§°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Á¶±â ¹ß°ß, ¼ö¼úÀû ¾ÈÁ¤È­, Áõ°Å¿¡ ±â¹ÝÇÑ ¾à¸®ÇÐ ¹× ÀçȰ Àü·«Àº ±â´ÉÀû °á°ú¸¦ ±Ø´ëÈ­Çϰí ÇÕº´ÁõÀ» ÁÙÀ̸ç ȯÀÚÀÇ »îÀÇ ÁúÀ» °³¼±ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

¿Ü°úÀû °³ÀÔ, ¾à¹° Ä¡·á, ½Å°æ º¸È£ÀÇ Çõ½ÅÀº SCI Ä¡·á¸¦ ¾î¶»°Ô ¹ßÀü½Ã۰í Àִ°¡?

¼ö¼úÀû °¨¾Ð¼ú°ú ¾ÈÁ¤È­¼úÀº ±â¼úÀÇ ¹ßÀüÀ¸·Î º¸´Ù Á¤È®Çϰí ÃÖ¼Òħ½ÀÀûÀÎ Á¢±ÙÀÌ °¡´ÉÇØÁ® ¼ö¼ú À§ÇèÀ» ÁÙÀ̰í Á¶±â °Åµ¿À» µ½´Â ±Ùº»ÀûÀÎ Ä¡·á¹ýÀ¸·Î ¿©ÀüÈ÷ Áß¿äÇÑ Ä¡·á¹ýÀÔ´Ï´Ù. ô¼ö ³»ºñ°ÔÀ̼Ç, ¼ö¼ú Áß ¿µ»óÁø´Ü, ½Å°æ ¸ð´ÏÅ͸µÀº Á¤·ÄÀÇ Á¤È®µµ¸¦ ³ôÀ̰í, À̹漺 ¼Õ»óÀ» ÃÖ¼ÒÈ­ÇÏ¿© ¼ö¼ú °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù.

ÀϺΠ»ç·Ê¿¡¼­ °í¿ë·® ¸ÞÆ¿ÇÁ·¹µå´Ï¼Ö·ÐÀ» Æ÷ÇÔÇÑ ¾à¸®ÇÐÀû Á¢±Ù¹ýÀÌ ÀçÆò°¡µÇ°í ÀÖÀ¸¸ç, »õ·Î¿î ½Å°æ º¸È£ ¿ä¹ýÀº ¿°Áõ, ¼¼Æ÷ »ç¸ê, »êÈ­ ½ºÆ®·¹½º¸¦ Ç¥ÀûÀ¸·Î »ï°í ÀÖ½À´Ï´Ù. ¸±Á¹, ¹Ì³ë»çÀÌŬ¸°, Áٱ⼼Æ÷ À¯·¡ »ý¹°ÇÐÀû Á¦Á¦ µî 2Â÷ Àå¾Ö¸¦ ¾ïÁ¦ÇÏ°í ½Å°æ Àç»ýÀ» ÃËÁøÇÏ´Â ¾à¹°¿¡ ´ëÇÑ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í º´ÇàÇÏ¿© ÁýÁßÀûÀÎ ÀçȰġ·á¿Í ¿Ü°ñ°Ý ¹× Àü±âÀڱر⠵îÀÇ º¸Á¶±â¼úÀÌ ½Å°æ°¡¼Ò¼º°ú ±â´É ȸº¹À» ³ôÀ̰í ÀÖ½À´Ï´Ù.

±Þ¼º±â SCI Ä¡·á ¼ö¿ä¸¦ ÁÖµµÇϴ ȯÀÚÃþ°ú ÀÇ·á ½Ã½ºÅÛÀº?

ÀþÀº ¼ºÀÎ ³²¼ºÀº À§ÇèÇÑ È°µ¿¿¡ ³ëÃâµÉ ±âȸ°¡ ¸¹±â ¶§¹®¿¡ Àü ¼¼°èÀûÀ¸·Î ±Þ¼º ô¼ö¼Õ»ó »ç·ÊÀÇ »ó´ç ºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù. ±×·¯³ª Àα¸ÀÇ °í·ÉÈ­´Â ƯÈ÷ ¼±Áø±¹¿¡¼­ Ãæ°ÝÀÌ ÀûÀº ³«»óÀ¸·Î ÀÎÇÑ SCI Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÀ±Þ½Ç, ¿Ü»ó¼¾ÅÍ, Àü¹® ½Å°æÀçȰÀÇÇаú°¡ ÁÖ¿ä Ä¡·á Æ÷ÀÎÆ®À̸ç, Àå±âÀûÀÎ °ü¸®¸¦ À§Çؼ­´Â ´ÙÇÐÁ¦Àû ÃßÀû°üÂû°ú Áö¿ª ±â¹Ý Áö¿øÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù.

ºÏ¹Ì´Â ¹ß»ý·ü ÃßÀû, ÷´Ü ¿Ü»ó ´ëÀÀ ½Ã½ºÅÛ, ±Þ¼º±â ÀÌÈÄ Ä¡·á ÀÎÇÁ¶óÀÇ °¡¿ë¼º Ãø¸é¿¡¼­ ¼±µÎ¸¦ ´Þ¸®°í ÀÖ½À´Ï´Ù. À¯·´Àº źźÇÑ ½Å°æ ÀçȰ ÇÁ·Î±×·¥°ú SCI Ä¡·áÁ¦ÀÇ ÀÓ»ó½ÃÇèÀÌ ÁøÇà ÁßÀÔ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ±Þ¼ÓÇÑ µµ½ÃÈ­¿Í ÀÚµ¿Â÷ »ç°í Áõ°¡·Î ÀÎÇØ ¿Ü»ó Ä¡·á¿Í ôÃß ¼ö¼ú ´É·Â¿¡ ´ëÇÑ Áö¿ªÀû ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í ¾ÆÇÁ¸®Ä« ÀϺΠÁö¿ª¿¡¼­´Â Á¶±â °³ÀÔ°ú Àå±âÀûÀÎ Áö¿øÀÇ °ÝÂ÷°¡ ¿©ÀüÈ÷ ½É°¢ÇÑ ¹®Á¦·Î ³²¾ÆÀÖ½À´Ï´Ù.

ÀÇ·áÁ¤Ã¥, ¿¬±¸ºñ, Áö¿ø±â¼úÀº ½ÃÀå °³Ã´¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

SCI°¡ °øÁߺ¸°Ç ¹®Á¦¶ó´Â Á¤Ã¥Àû Â÷¿øÀÇ ÀνÄÀº ÀÀ±Þ ÀÇ·á ¼­ºñ½º, ¼ö¼ú ´É·Â, Àå±â ÀçȰ¿¡ ´ëÇÑ ÅõÀÚ¸¦ °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. Àü±¹ÀûÀÎ ¿Ü»ó µî·Ï, ÀÓ»ó °¡À̵å¶óÀÎ, SCI ¿ì¼ö ¼¾ÅÍ¿¡ ´ëÇÑ ÀÚ±Ý Áö¿øÀº Ç¥ÁØÈ­µÈ Ä¡·á Á¦°ø°ú ¿¬±¸ Âü¿©¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀϺΠÁö¿ª¿¡¼­´Â ¿Ü°úÀû °³ÀÔ, ÀçȰ ¹× À̵¿ º¸Á¶±â±¸¿¡ ´ëÇÑ º¸Çè Àû¿ëÀÌ °³¼±µÇ¾î Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

SCI ¿¬±¸, ƯÈ÷ ½Å°æ Àç»ý, ô¼ö ÀÓÇöõÆ®, ÷´Ü ÀçȰ ·Îº¿¿¡ ¸¹Àº ÀÚ±ÝÀÌ ÅõÀԵǰí ÀÖ½À´Ï´Ù. Çаè, »ý¸í°øÇÐ ±â¾÷, Á¤ºÎ ±â°üÀÇ Çù·Â üÁ¦°¡ ÀÓ»ó Çõ½ÅÀÇ ÇѰ踦 ³ÐÇô°¡°í ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí º¸Á¶ ÀåÄ¡, ³ú-ÄÄÇ»ÅÍ ÀÎÅÍÆäÀ̽º, ½Å°æ º¸Ã¶Àº ô¼ö ¼Õ»ó ȯÀÚÀÇ ÀÚ¸³°ú ȸº¹¿¡ »õ·Î¿î ±¹¸éÀ» °¡Á®¿À°í, ÅëÇÕ Ä¡·á °æ·ÎÀÇ ¹Ì·¡ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.

±Þ¼º±â SCI Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

±Þ¼º±â SCI Ä¡·á ½ÃÀåÀº Àü ¼¼°èÀûÀ¸·Î ¿Ü»ó ¹ß»ý·ü Áõ°¡, ÀÎ½Ä Áõ°¡, ÀÀ±Þ ´ëÀÀ ½Ã½ºÅÛÀÇ °³¼±, ¼ö¼ú ¹× ½Å°æ º¸È£ Àü·«ÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀ¸·Î ÀÎÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü¹® ½Å°æ ÀçȰ ¼­ºñ½ºÀÇ °¡¿ë¼º Áõ°¡¿Í ±â´É ȸº¹À» Áö¿øÇÏ´Â º¸Á¶ ±â¼úÀÇ Çõ½Åµµ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó °¡À̵å¶óÀÎÀÇ ¹ßÀü°ú ¿¬±¸ÀÇ ºñ¾àÀûÀÎ ¹ßÀüÀÌ °¡¼ÓÈ­µÊ¿¡ µû¶ó ±Þ¼º±â SCI¿¡ ´ëÇÑ Ç¥ÁØ Ä¡·á´Â Áß¿äÇÑ Àüȯ±â¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù.

ÇâÈÄ ½ÃÀåÀÇ ±ËÀûÀº »õ·Î¿î Ä¡·á¹ý, ¼ö¼ú Çõ½Å, Àå±â Ä¡·á ¸ðµ¨ÀÌ °á°ú °³¼±°ú ÀÚÀ²¼º ȸº¹¿¡ ¾ó¸¶³ª È¿°úÀûÀ¸·Î À¶ÇյǴÀ³Ä¿¡ µû¶ó Çü¼ºµÉ °ÍÀÔ´Ï´Ù. ô¼ö Àç»ý°ú ±â´É ȸº¹¿¡ ´ëÇÑ Àü ¼¼°èÀÇ °ü½ÉÀÌ ÁýÁߵǰí ÀÖ´Â °¡¿îµ¥, ±Þ¼º±â SCI Ä¡·á°¡ Â÷¼¼´ë ½Å°æ ¿Ü»ó ¹× ÀçȰ ÀÇ·áÀÇ Ãʼ®ÀÌ µÉ ¼ö ÀÖÀ»±î?

ºÎ¹®

À¯Çü(¿ÏÀü ô¼ö ¼Õ»ó, ºÒ¿ÏÀü ô¼ö ¼Õ»ó), ÃÖÁ¾ »ç¿ë(º´¿ø, ¿Ü»ó ¼¾ÅÍ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 43°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÍ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>& Áß±¹ <>& ¸ß½ÃÄÚ <>& ij³ª´Ù <>&EU <>& ÀϺ» <>& Àεµ <>& ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Acute Spinal Cord Injury Market to Reach US$8.7 Billion by 2030

The global market for Acute Spinal Cord Injury estimated at US$6.7 Billion in the year 2024, is expected to reach US$8.7 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Complete Spinal Cord Injury, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$6.2 Billion by the end of the analysis period. Growth in the Incomplete Spinal Cord Injury segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 8.3% CAGR

The Acute Spinal Cord Injury market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Acute Spinal Cord Injury (SCI) Treatment Market - Key Trends & Drivers Summarized

Why Is Acute Spinal Cord Injury a Critical Therapeutic Priority in Emergency, Trauma, and Neurorehabilitation Medicine?

Acute spinal cord injury (SCI) is a sudden, traumatic event resulting in partial or complete disruption of sensory, motor, and autonomic functions below the injury site. It represents one of the most complex and devastating neurological emergencies, often arising from vehicular accidents, falls, sports injuries, or violence. Immediate intervention is vital, as irreversible secondary damage-driven by ischemia, inflammation, and excitotoxicity-can rapidly follow the initial trauma, exacerbating long-term disability.

With high societal and economic burden, acute SCI is increasingly prioritized in trauma and neurosurgical protocols worldwide. Early recognition, surgical stabilization, and evidence-based pharmacologic and rehabilitative strategies are essential to maximizing functional outcomes, reducing complications, and improving quality of life for affected individuals.

How Are Innovations in Surgical Intervention, Pharmacotherapy, and Neuroprotection Advancing SCI Care?

Surgical decompression and stabilization remain cornerstone treatments, with technological advances enabling more precise and minimally invasive approaches that reduce operative risk and support early mobilization. Spinal navigation, intraoperative imaging, and neuro-monitoring are improving surgical outcomes by enhancing alignment accuracy and minimizing iatrogenic damage.

Pharmacological approaches, including high-dose methylprednisolone in select cases, are being reassessed, while emerging neuroprotective therapies are targeting inflammation, apoptosis, and oxidative stress. Research is advancing into agents such as riluzole, minocycline, and stem cell-derived biologics to limit secondary damage and promote neuroregeneration. In parallel, intensive rehabilitation and assistive technologies such as exoskeletons and electrical stimulation devices are enhancing neuroplasticity and functional recovery.

Which Patient Demographics and Healthcare Systems Are Driving Demand for Acute SCI Treatment?

Young adult males account for a large proportion of acute SCI cases globally due to their higher exposure to risk-prone activities. However, aging populations are contributing to a rise in SCI from low-impact falls, especially in developed countries. Emergency departments, trauma centers, and specialized neurorehabilitation units are the primary points of care, with long-term management often requiring multidisciplinary follow-up and community-based support.

North America leads in terms of incidence tracking, advanced trauma response systems, and availability of post-acute care infrastructure. Europe follows with robust neurorehabilitation programs and ongoing clinical trials in SCI therapeutics. Asia-Pacific is witnessing rising caseloads amid rapid urbanization and increasing motor vehicle accidents, driving regional investments in trauma care and spinal surgery capabilities. In Latin America and parts of Africa, gaps in early intervention and long-term support remain critical challenges.

How Are Health Policies, Research Funding, and Assistive Technologies Influencing Market Development?

Policy-level recognition of SCI as a public health concern is accelerating investment in emergency medical services, surgical capacity, and long-term rehabilitation. National trauma registries, clinical guidelines, and funding for SCI centers of excellence are facilitating standardized care delivery and research participation. Insurance coverage for surgical intervention, rehabilitation, and mobility aids is also improving in several regions, expanding treatment access.

Significant funding is being directed toward SCI research, particularly in neuroregeneration, spinal cord implants, and advanced rehabilitation robotics. Collaborative efforts between academia, biotech firms, and government agencies are pushing the boundaries of clinical innovation. Wearable assistive devices, brain-computer interfaces, and neuroprosthetics are offering new dimensions of independence and recovery for individuals with SCI, creating future opportunities for integrated treatment pathways.

What Are the Factors Driving Growth in the Acute SCI Treatment Market?

The acute SCI treatment market is expanding due to increasing global trauma incidence, heightened awareness, improved emergency response systems, and rapid advancements in surgical and neuroprotective strategies. Growth is also supported by the rising availability of specialized neurorehabilitation services and innovation in assistive technologies that support functional restoration. As clinical guidelines evolve and research breakthroughs accelerate, the standard of care for acute SCI is undergoing meaningful transformation.

Looking ahead, the market’s trajectory will be shaped by how effectively emerging therapies, surgical innovations, and long-term care models converge to improve outcomes and restore autonomy. As global focus intensifies on spinal cord regeneration and functional recovery, could acute SCI treatment become a cornerstone of next-generation neurotrauma and rehabilitation medicine?

SCOPE OF STUDY:

The report analyzes the Acute Spinal Cord Injury market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Complete Spinal Cord Injury, Incomplete Spinal Cord Injury); End-Use (Hospitals, Trauma Centers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â